Highlights from the 14th International Symposium on MDS


Insights into the Mechanism of Action of Lenalidomide in Patients with Del(5q)
Benjamin Ebert, MD, PhD

Begin


The Future of Genomics in MDS: What Will We Require for Our Clinical Daily Practice?
Jaroslaw P. Maciejewski, MD, PhD, FACP

Begin


Aging, CHIP and MDS
David P. Steensma, MD, FACP

Begin


Part One: Molecular Screening and Treatment in MDS, Mutant IDH as a Target, and Enasidenib
Part Two: Luspatercept in Lower Risk MDS: Updates from the PACE Study and Phase 2 Studies in Patients with Anemia

Eytan M. Stein, MD

Begin

Managing MDS would like to recognize and thank Celgene Corporation for their educational support of ManagingMDS.com

©2017 MediCom Worldwide, Inc. All rights reserved